Anne Phelan
Directeur Technique/Scientifique/R&D chez BENEVOLENTAI
Profil
Anne Phelan is currently the Director at BenevolentAI Cambridge Ltd., the Chief Scientific Officer at BenevolentAI Ltd., and the Chief Scientific Officer at BenevolentAI SA. Previously, she worked as the Executive Vice President & Head-Research at MISSION Therapeutics Ltd.
in 2018 and as the Chief Operating Officer & Head-Pharmacology at Pfizer Inc. from 2014 to 2015.
Dr. Phelan obtained her undergraduate and doctorate degrees from the University of Liverpool.
Postes actifs de Anne Phelan
| Sociétés | Poste | Début |
|---|---|---|
| BENEVOLENTAI | Directeur Technique/Scientifique/R&D | 01/11/2019 |
BenevolentAI Cambridge Ltd.
 BenevolentAI Cambridge Ltd. Miscellaneous Commercial ServicesCommercial Services BenevolentAI Cambridge Ltd. develops novel small molecule therapeutics, in particular in the areas of CNS, pain and inflammation. It specializes in drug development, project management and translational medicine. The company was founded on November 26, 2003 and is headquartered in London, the United Kingdom. | Directeur/Membre du Conseil | 03/01/2019 |
BenevolentAI Ltd.
 BenevolentAI Ltd. Packaged SoftwareTechnology Services Part of BenevolentAI SA, BenevolentAI Ltd. develops artificial intelligence applications. The company is based in London, UK. The British company was founded in 2015 by Kenneth Patrick Mulvany, Ivan Griffin, Michael Brennan. BenevolentAI was acquired by Odyssey Acquisition SA on April 22, 2022 for $1,087.33 million. | Directeur Technique/Scientifique/R&D | 01/09/2019 |
Anciens postes connus de Anne Phelan
| Sociétés | Poste | Fin |
|---|---|---|
MISSION Therapeutics Ltd.
 MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | Directeur Technique/Scientifique/R&D | 01/11/2018 |
| PFIZER, INC. | Corporate Officer/Principal | 01/10/2015 |
Formation de Anne Phelan
| University of Liverpool | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BENEVOLENTAI | Health Technology |
| PFIZER, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
BenevolentAI Cambridge Ltd.
BenevolentAI Cambridge Ltd. Miscellaneous Commercial ServicesCommercial Services BenevolentAI Cambridge Ltd. develops novel small molecule therapeutics, in particular in the areas of CNS, pain and inflammation. It specializes in drug development, project management and translational medicine. The company was founded on November 26, 2003 and is headquartered in London, the United Kingdom. | Commercial Services |
BenevolentAI Ltd.
BenevolentAI Ltd. Packaged SoftwareTechnology Services Part of BenevolentAI SA, BenevolentAI Ltd. develops artificial intelligence applications. The company is based in London, UK. The British company was founded in 2015 by Kenneth Patrick Mulvany, Ivan Griffin, Michael Brennan. BenevolentAI was acquired by Odyssey Acquisition SA on April 22, 2022 for $1,087.33 million. | Technology Services |
MISSION Therapeutics Ltd.
MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
